Adult Growth Hormone Deficiency (AGHD) Market to Observe Impressive Growth During the Forecast Period (2022-2032), Evaluates DelveInsight | Key Companies - Novo Nordisk (Sogroya/somapacitan-beco) Ascendis Pharma (TransCon hGH), OPKO Health (Somatrogon)

As per DelveInsight, the Adult Growth Hormone Deficiency (AGHD) Market is anticipated to evolve immensely in the coming years owing to the extensive R&D activities by academias and pharma giants such as Ascendis Pharma, OPKO Health, and others in the therapeutics market. Moreover, the rising cases of Adult Growth Hormone Deficiency, the improvement in the diagnosis methodologies, and incremental healthcare spending worldwide are also expected to fuel the market growth.

DelveInsight's "Adult Growth Hormone Deficiency (AGHD) Market Insights, Epidemiology, and Market Forecast 2032" report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Adult Growth Hormone Deficiency Market Size and Share in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).

The Adult Growth Hormone Deficiency market report covers emerging drugs, treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of opportunities and assess the underlying potential of the market.

Adult Growth Hormone Deficiency (AGHD): An Overview
Adult Growth Hormone Deficiency (AGHD) is a medical condition that occurs when the pituitary gland in the brain does not produce enough growth hormone. Most cases of Adult Growth Hormone Deficiency (AGHD) result from damage to the pituitary gland caused by a pituitary tumor or by treatment for this using surgery and/or radiotherapy. Adult Growth Hormone Deficiency (AGHD) is treated with growth hormone replacement therapy. The growth hormone that is used is an artificial preparation that individuals can administer themselves.

Adult Growth Hormone Deficiency Market Key Facts
• According to D B Allen et al., about 15%-20% of the cases represent the transition of childhood GH deficiency into adulthood.
• As per Jana Bujanova et al., the estimated prevalence of AGHD in the UK is approximately 1 in 10 000 (a total of approximately 6380 patients). If Childhood-onset GH deficiency is added to this number, then prevalence is 1 in 10 000 to 1 in 3500.
• In a study, the author found that a greater proportion of Japanese adults had AO GHD than CO GHD, a finding similar to those of previous studies in Caucasian adults. In contrast, in a previous study of Japanese adults with GHD, only 45% of participants were reported to have AO GHD. [Akira Shimatsu et al.,2011]
• According to Growth Hormone Foundation estimates, more than 50,000 adults in the United States are growth hormone deficient, and 6,000 new cases are reported each year, including GHD children who transition to GHD as an adult.

Adult Growth Hormone Deficiency (AGHD) Market
The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted Adult Growth Hormone Deficiency market size by analyzing the impact of current and emerging therapies in the market. It also provides a detailed assessment of the market drivers & barriers, unmet needs, and emerging technologies.

The report gives complete detail of the Adult Growth Hormone Deficiency market trend for each marketed drug and late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action (MOA), competition with other therapies, brand value, their impact on the market and view of the key opinion leaders.

Discover How Adult Growth Hormone Deficiency Market will Grow by 2032:
https://www.delveinsight.com/report-store/adult-growth-hormone-deficiency-aghd-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Adult Growth Hormone Deficiency (AGHD) Epidemiology
The epidemiology section covers detailed insights into the historical and current Adult Growth Hormone Deficiency patient pool and forecasted trends for every seven major countries (7MM) from 2019 to 2032.

The Report Covers the Adult Growth Hormone Deficiency (AGHD) Epidemiology Segmented as -
• Prevalent Cases of Adult Growth Hormone Deficiency in 7MM [2019-2032]
• Diagnosed Prevalent Cases Based on Onset of GHD [Childhood Onset GHD, Adult Onset GHD] in 7MM [2019-2032]
• Diagnosed and Treatable Cases of Adult Growth Hormone Deficiency in the 7MM [2019-2032]
• Gender-specific Prevalent Cases of Adult Growth Hormone Deficiency in 7MM [2019-2032]

Get Key Insights Into the Evolving Adult Growth Hormone Deficiency Epidemiology Trends:
https://www.delveinsight.com/report-store/adult-growth-hormone-deficiency-aghd-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Adult Growth Hormone Deficiency (AGHD) Drugs Uptake and Pipeline Development Activities
The drugs' uptake section focuses on the rate of uptake of the potential drugs recently launched in the Adult Growth Hormone Deficiency market or expected to be launched during the study period. The analysis covers Adult Growth Hormone Deficiency market uptake by drugs, patient uptake by therapies, and sales of each drug.

The report's drugs uptake section helps in understanding the drugs with the most rapid uptake and reasons behind the maximal use of new drugs and allows the comparison of the drugs based on market share and size, which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

The report also covers the Adult Growth Hormone Deficiency (AGHD) Pipeline Development Activities and provides valuable insights about different therapeutic candidates in Phase II and Phase III stages and the key companies in the market involved in developing targeted therapeutics. It also analyses recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Explore More About Ongoing Pipeline Development Activities:
https://www.delveinsight.com/sample-request/adult-growth-hormone-deficiency-aghd-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Adult Growth Hormone Deficiency Therapeutics Assessment
Currently, a few pharma and biotech giants are developing therapies for Adult Growth Hormone Deficiency (AGHD). Ascendis Pharma is leading the therapeutics with its Adult Growth Hormone Deficiency (AGHD) drug candidates in the mid to advanced stage of clinical development.

The Leading Players in the Adult Growth Hormone Deficiency (AGHD) Therapeutics Market Include:
• Novo Nordisk
• Ascendis Pharma
• Genexine
And Many Others

Adult Growth Hormone Deficiency (AGHD) Emerging and Marketed Drugs Covered in the Report Include:
• Sogroya (somapacitan-beco): Novo Nordisk
• TransCon hGH: Ascendis Pharma
• Somatrogon: OPKO Health
And Many More

Learn More About the Emerging Therapies & Key Companies in the Adult Growth Hormone Deficiency Therapeutics Market:
https://www.delveinsight.com/sample-request/adult-growth-hormone-deficiency-aghd-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Table of Content (TOC)
1. Key Insights
2. Executive Summary
3. Adult Growth Hormone Deficiency Competitive Intelligence Analysis
4. Adult Growth Hormone Deficiency Market Overview at a Glance
5. Adult Growth Hormone Deficiency Background and Overview
6. Adult Growth Hormone Deficiency Patient Journey
7. Adult Growth Hormone Deficiency Epidemiology and Patient Population
8. Adult Growth Hormone Deficiency Treatment Algorithm, Current Treatment, and Medical Practices
9. Adult Growth Hormone Deficiency Unmet Needs
10. Key Endpoints of Adult Growth Hormone Deficiency Treatment
11. Adult Growth Hormone Deficiency Marketed Products
12. Adult Growth Hormone Deficiency Emerging Therapies
13. Adult Growth Hormone Deficiency Seven Major Market Analysis
14. Attribute Analysis
15. Adult Growth Hormone Deficiency Market Outlook (7 major markets)
16. Adult Growth Hormone Deficiency Access and Reimbursement Overview
17. KOL Views on the Adult Growth Hormone Deficiency Market.
18. Adult Growth Hormone Deficiency Market Drivers
19. Adult Growth Hormone Deficiency Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
*The table of contents is not exhaustive; the final content may vary.

Download the Sample PDF to Get Detailed Insights About the Report's Offerings:
https://www.delveinsight.com/sample-request/adult-growth-hormone-deficiency-aghd-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Contact Info:
Shruti Thakur
Manager (Marketing & Branding)
Email: info@delveinsight.com

428, D21 Corporate Park, Sector-21, Dwarka, New Delhi-110077, India

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

This release was published on openPR.